352 Chapter 14 SUPPLEMENTAL MATERIALS Table S1: Baseline characteristics of the study sample compared to the original LoDoCo2 cohort Characteristics Current study (n = 945) LoDoCo2 (n = 5522) Age - yr (SD) 65 (8.5) 66 (8.6) Female sex - n (%) 156 (16.5) 746 (13.5) Current smoker - n (%) 148 (15.7) 648 (11.7) Hypertension - n (%) 482 (51.0) 2808 (50.9) Diabetes - n (%) 176 (18.6) 1007 (18.2) Kidney function stage 3a* - n (%) 96 (10.2) 306 (5.5) Prior acute coronary syndrome - n (%) 777 (82.2) 4658 (84.4) Prior coronary revascularization 863 (91.3) 4621 (83.7) Coronary-artery bypass grafting- n (%) 122 (12.9) 710 (12.9) Percutaneous coronary intervention- n (%) 798 (84.4) 4177 (75.6) History of atrial fibrillation - n (%) 146 (15.4) 649 (11.8) History of gout - n (%) 86 (9.1) 446 (8.1) Medication use Single antiplatelet therapy - n (%) 645 (68.3) 3701 (67.0) Dual antiplatelet therapy - n (%) 171 (18.1) 1280 (23.2) Anticoagulant - n (%) 160 (16.9) 672 (12.2) No antiplatelet agent or anticoagulant - n (%) 1 (0.1) 15 (0.3) Statin - n (%) 850 (89.9) 5188 (94.0) Ezetimibe - n (%) 191 (20.2) 1073 (19.4) Any lipid-lowering agent - n (%) 890 (94.2) 5335 (96.6) Renin–angiotensin inhibitor - n (%) 672 (71.1) 3960 (71.7) Beta-blocker - n (%) 658 (69.6) 3427 (62.1) Calcium-channel blocker - n (%) 205 (21.7) 1244 (22.5) *Stage 3a kidney function refers to an estimated glomerular filtration rate of 45 to 59 ml per minute per 1.73 m2 (mildly to moderately decreased). Stages are based on the Kidney Disease: Improving Global Outcomes (KDIGO) Clinical Practice Guideline for Acute Kidney Injury.1 Abbreviations: SD: standard deviation
RkJQdWJsaXNoZXIy MTk4NDMw